1. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.
- Author
-
Moreno A, Quereda C, Montes M, Pérez-Elías MJ, Casado JL, Rodríguez-Sagrado MA, Mateos ML, Dronda F, Bárcena R, Del Campo S, and Moreno S
- Subjects
- Antiretroviral Therapy, Highly Active adverse effects, Antiviral Agents administration & dosage, Antiviral Agents adverse effects, Coinfection drug therapy, Drug Therapy, Combination adverse effects, Drug Therapy, Combination methods, Female, HIV Infections complications, HIV Integrase Inhibitors administration & dosage, HIV Integrase Inhibitors adverse effects, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors adverse effects, Hepatitis C complications, Humans, Interferon-alpha administration & dosage, Interferon-alpha adverse effects, Interferon-alpha therapeutic use, Liver Cirrhosis virology, Male, Middle Aged, Oligopeptides administration & dosage, Oligopeptides adverse effects, Polyethylene Glycols administration & dosage, Polyethylene Glycols adverse effects, Polyethylene Glycols therapeutic use, Proline administration & dosage, Proline adverse effects, Proline therapeutic use, Pyrrolidinones administration & dosage, Pyrrolidinones adverse effects, Raltegravir Potassium, Recombinant Proteins administration & dosage, Recombinant Proteins adverse effects, Recombinant Proteins therapeutic use, Ribavirin administration & dosage, Ribavirin adverse effects, Ribavirin therapeutic use, Antiretroviral Therapy, Highly Active methods, Antiviral Agents therapeutic use, HIV Infections drug therapy, HIV Integrase Inhibitors therapeutic use, HIV Protease Inhibitors therapeutic use, Hepatitis C drug therapy, Liver Cirrhosis complications, Oligopeptides therapeutic use, Proline analogs & derivatives, Pyrrolidinones therapeutic use
- Published
- 2012
- Full Text
- View/download PDF